Centhaquin

57961-90-7

331.45

DMSO : 62.5 mg/mL (188.57 mM; Need ultrasonic)

Others

Centhaquine (Centhaquin; PMZ-2010) is a novel agent has the potential for treatment of haemorrhagic shock. Centhaquine (Centhaquin; PMZ-2010) can augment cardiac output, reduce systemic vascular resistance in haemorrhagic models^[1][2]. In Vivo: Centhaquine (Centhaquin) (intravenous injection, 0.01-1.0 mg/kg; intraduodenal administration 1.0-2.5 mg/kg) lowers the blood pressure and reduced the heart rate of anaesthetized and unanaesthetized (decerebrate) cat in a dose-dependent manner^[1].
Centhaquine (Centhaquin) (intravertebral arterial injection; 5-10 ug) or by topical application to the exposed ventral surface of medulla or floor of the fourth ventricle causes hypotension and bradycardia as well as reduced the excitability of the vasomotor loci^[1].
Centhaquine (Centhaquin; PMZ-2010) (intravenous administration; 0.015mg/kg) can attenuate the deleterious effects of catecholamines, improving both the macro- and microcirculation during CPR^[2].